Nuvalent, Inc.
NUVLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Nuvalent, Inc. (NUVL) is listed under Biotechnology. With a market capitalization of $9.79B, it sits in mid-cap territory. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-se.
Market Cap
$9.79B
Beta
1.14
P/E (TTM)
—
P/E (Fwd)
-30.12
EPS (TTM)
$-6.06
EPS (Fwd)
$-4.12
ROE
-41.2%
ROA
-22.5%
Cash
$1.29B
Total Debt
$0
Free CF
-$180.4M
52W Change
45.1%
Annual Financials
Cash vs Debt
Nuvalent, Inc. reports $1.29B in cash and $0 in total debt. The company is burning cash, with free cash flow at -$180.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -41.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing NUVL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.